Forum on Drug Discovery, Development, and Translation: 10 Year Review: 2011-2020 (2021)

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Forum Sponsorship and Membership SPONSORS MEMBERS (as of December 2020)  Financial support for the forum is derived from government agencies, industry Forum membership includes a diverse sponsors, private foundations, and nonprofit associations. range of stakeholders from multiple sectors, *Sponsors of the forum as of December 2020. including government, biopharmaceutical industry, biomedical research funders and Government GlaxoSmithKline sponsors, academia, foundations, Biomedical Advanced Research and Janssen Research & Development, LLC Development Authority* Johnson & Johnson* consortia, disease advocacy, and patient- Center for Drug Evaluation and Research, Merck & Co., Inc.* focused groups. FDA* Novartis Pharmaceuticals Corporation Centers for Medicare & Medicaid Services Pfizer Inc. Robert Califf (Co-Chair) National Cancer Institute, NIH* Sanofi* Verily and Google Health National Center for Advancing Translational Schering-Plough Research Institute Gregory Simon (Co-Chair) Sciences, NIH* Takeda Pharmaceuticals, Inc.* Kaiser Permanente Washington Health National Center for Research Resources, NIH UnitedHealth Group Research Institute; University of Washington National Institute of Allergy and Infectious Diseases, NIH* Private Foundation Amy Abernethy National Institute of Mental Health, NIH* Burroughs Wellcome Fund* Office of the Commissioner, FDA National Institute of Neurological Disorders CDC Foundation Christopher Austin and Stroke, NIH* Doris Duke Charitable Foundation National Center for Advancing Translational Office of Rare Diseases Research, NIH Eli Lilly and Company Foundation Sciences, NIH Office of Science Policy, NIH* Fondation Mérieux Linda Brady U.S. Department of State National Institute of Mental Health, NIH U.S. Department of Veterans Affairs Nonprofit Organizations Barry Coller American Diabetes Association The Rockefeller University Industry American Society for Microbiology Abbott Pharmaceuticals Association of American Medical Colleges* Thomas Curran AbbVie Inc. Blue Cross Blue Shield Association Children’s Mercy, Kansas City Amgen* Critical Path Institute* Richard Davey AstraZeneca* FasterCures, Milken Institute* National Institute of Allergy and Infectious Auven Therapeutics LLLP Foundation for the National Institutes Diseases, NIH Biogen* of Health* Katherine Dawson Bristol-Myers Squibb Friends of Cancer Research* Biogen Eli Lilly and Company* Howard Hughes Medical Institute Entelos, Inc. March of Dimes James Doroshow Genentech/Roche New England Journal of Medicine* National Cancer Institute, NIH 34 

Forum Sponsorship and Membership Membership Jeffrey Drazen Ellen Sigal New England Journal of Medicine Friends of Cancer Research Carlos Garner Lana Skirboll Eli Lilly and Company Sanofi Julie Gerberding Amir Tamiz Merck & Co., Inc. National Institute of Neurological Deborah Hung Disorders and Stroke, NIH Harvard Medical School Ann Taylor Esther Krofah AstraZeneca FasterCures, Milken Institute Pamela Tenaerts Lisa LaVange Clinical Trials Transformation University of North Carolina Initiative, Duke University Ross McKinney, Jr. Joanne Waldstreicher Association of American Medical Colleges Johnson & Johnson Joseph Menetski Robert Walker Foundation for the National Institutes Biomedical Advanced Research of Health and Development Authority Arti Rai Jonathan Watanabe ACKNOWLEDGMENTS Duke University School of Law University of California, Irvine, School of Pharmacy and Thanks goes to the current and former Mark Rogge co-chairs of the forum—Edward W. Holmes Pharmaceutical Sciences Takeda Pharmaceuticals, Inc. Carrie Wolinetz (2005–2008), Gail H. Cassell (2005–2011), Kelly Rose Office of Science Policy, NIH Jeffrey M. Drazen (2008–2013), Steven Burroughs Wellcome Fund Alastair Wood K. Galson (2011–2017), Russ B. Altman Susan Schaeffer Vanderbilt University (2015–2018), Robert M. Califf (2018–present), Patients’ Academy for Research Advocacy Janet Woodcock and Gregory E. Simon (2019–present)—for Center for Drug Evaluation and their contributions and leadership. Additional Joseph Scheeren Research, FDA thanks goes to former forum members and Critical Path Institute Anantha Shekhar advisers as well as former staff who provided University of Pittsburgh thoughtful input, guidance, and support for Jay Siegel forum activities and publications. Retired 35